News

Apogenix also announced the commencement of Apocept Phase I trial in MDS patients in Germany. Endpoints of the open-label study include efficacy (improvement of erythropoiesis), safety, and tolerability

Combining the needs of multiple commercial teams, Veeva’s CRM solution improves user adoption and sales effectiveness, while reduces cost and complexity. iRep, a transformative sales effectiveness tool, combines

Under the agreement, DNA Link gained licensing rights to leverage Affymetrix’ microarray technology and the KFDA-cleared GeneChip System 3000Dx v.2 to develop and commercialize a forensic test AccuIDChip,

As part of the analysis, performed at more than 80 US locations, patients were given the combination of ZYBRESTAT (fosbretabulin tromethamine or CA4P) and Avastin (bevacizumab) and evaluated

Warner expects to commercially launch Delzicol in March 2013. Delzicol delayed-release capsules are indicated to treat patients with mild to moderate active ulcerative colitis and to maintain remission

Skyepharma received the notice of allowance for US patent application 13/428,548 entitled ‘Delayed Release Tablet with Defined Core Geometry’. The US patent planned to issue will expire in

The investigational iron-delivery drug SFP is presently in Phase 3 studies for the treatment of iron deficiency in hemodialysis patients. PRIME study demonstrated that regular SFP-iron administration by

The investigator-initiated study will be conducted at Maimonides Medical Center in Brooklyn, New York, to assess the utility of Lymphoseek in pinpointing lymph nodes most likely to contain

Naltrexone, an opioid receptor antagonist, is used primarily to manage alcohol dependence and opioid addiction. The approval will allow Elite to begin the commercial manufacturing and packaging of